<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Pulmonol</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr. Pulmonol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-0496</journal-id><journal-id journal-id-type="publisher-id">PPUL</journal-id><journal-title-group><journal-title>Pediatric Pulmonology</journal-title></journal-title-group><issn pub-type="ppub">8755-6863</issn><issn pub-type="epub">1099-0496</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7167964</article-id><article-id pub-id-type="doi">10.1002/ppul.24214</article-id><article-id pub-id-type="publisher-id">PPUL24214</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article: Infection and Immunity</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Infection and Immunity</subject></subj-group></subj-group></article-categories><title-group><article-title>The role of respiratory viruses in children with humoral immunodeficiency on immunoglobulin replacement therapy</article-title><alt-title alt-title-type="left-running-head">BENAVIDES&#x02010;NIETO <sc>et al.</sc></alt-title></title-group><contrib-group><contrib id="ppul24214-cr-0001" contrib-type="author"><name><surname>Benavides&#x02010;Nieto</surname><given-names>Marta</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="ppul24214-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="ppul24214-cr-0002" contrib-type="author" corresp="yes"><name><surname>M&#x000e9;ndez&#x02010;Echevarr&#x000ed;a</surname><given-names>Ana</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7455-9080</contrib-id><xref ref-type="aff" rid="ppul24214-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref><address><email>amendezes@yahoo.es</email></address></contrib><contrib id="ppul24214-cr-0003" contrib-type="author"><name><surname>del Rosal</surname><given-names>Teresa</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="ppul24214-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="ppul24214-cr-0004" contrib-type="author"><name><surname>Garc&#x000ed;a&#x02010;Garc&#x000ed;a</surname><given-names>Mar&#x000ed;a Luz</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4906-4227</contrib-id><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="ppul24214-cr-0005" contrib-type="author"><name><surname>Casas</surname><given-names>Inmaculada</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ppul24214-cr-0006" contrib-type="author"><name><surname>Pozo</surname><given-names>Francisco</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="ppul24214-cr-0007" contrib-type="author"><name><surname>de la Serna</surname><given-names>Olga</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="ppul24214-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="ppul24214-cr-0008" contrib-type="author"><name><surname>Lopez&#x02010;Granados</surname><given-names>Eduardo</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="ppul24214-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="ppul24214-cr-0009" contrib-type="author"><name><surname>Rodriguez&#x02010;Pena</surname><given-names>Rebeca</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="ppul24214-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="ppul24214-cr-0010" contrib-type="author"><name><surname>Calvo</surname><given-names>Cristina</given-names></name><degrees>MD, PhD</degrees><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6503-3423</contrib-id><xref ref-type="aff" rid="ppul24214-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="ppul24214-aff-0007">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="ppul24214-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Pediatric Infectious Diseases Department</named-content>
<institution>Hospital Universitario La Paz</institution>
<city>Madrid, Fundaci&#x000f3;n IdiPaz, Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0002">
<label><sup>2</sup></label>
<institution>Translational Research Network in Pediatric Infectious Diseases (RITIP)</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Pediatrics and Pneumology Department</named-content>
<institution>Severo Ochoa Hospital</institution>
<city>Legan&#x000e9;s, Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Respiratory Virus and Influenza Unit</named-content>
<institution>CNM, Instituto de Salud Carlos III</institution>
<city>Majadahonda, Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Paediatric Pneumology Department</named-content>
<institution>Hospital La Paz</institution>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Immunology Department</named-content>
<institution>Hospital Universitario La Paz</institution>
<city>Fundaci&#x000f3;n IdiPaz, Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ppul24214-aff-0007">
<label><sup>7</sup></label>
<institution>TEDDY Network (European Network of Excellence for Pediatric Clinical Research)</institution>
<city>Pavia</city>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ana M&#x000e9;ndez&#x02010;Echevarr&#x000ed;a, MD, PhD, Paediatrics and Infectious Diseases Department, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046, Madrid, Spain.<break/>
Email: 
<email>amendezes@yahoo.es</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>21</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2019</year></pub-date><volume>54</volume><issue>2</issue><issue-id pub-id-type="doi">10.1002/ppul.v54.2</issue-id><fpage>194</fpage><lpage>199</lpage><history><date date-type="received"><day>02</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 Wiley Periodicals, Inc. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 Wiley Periodicals, Inc.</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PPUL-54-194.pdf"/><abstract><title>Abstract</title><sec id="ppul24214-sec-0001"><title>Background</title><p>The role of viruses in children with respiratory tract infections and humoral immunodeficiencies has hardly been studied. We have evaluated these infections in children with humoral immunodeficiencies who required immunoglobulin replacement therapy, considering their relationship with symptoms, lung function, bacterial co&#x02010;infection, and outcomes.</p></sec><sec id="ppul24214-sec-0002"><title>Methods</title><p>We conducted a prospective case&#x02010;control study during a 1&#x02010;year period, including children with humoral immunodeficiencies receiving immunoglobulin replacement therapy. For each patient, at least one healthy family member was included. Respiratory samples for viral detection were taken every 1&#x02010;3 months, and in case of respiratory tract infections. Symptoms questionnaires were filled biweekly. Spirometry and sputum culture were performed in every episode.</p></sec><sec id="ppul24214-sec-0003"><title>Results</title><p>Sixty&#x02010;six episodes were analyzed in 14 patients (median age 12 years; IQR 7&#x02010;17), identifying 18 respiratory viruses (27.3%), being rhinovirus the most frequently isolated one (12/18; 66%). Positive viral episodes were associated with clinical symptoms (89% vs 43%), more frequent antibiotic treatment (44% vs 15%) or hospital admission (22% vs 0%) than negative ones. Patients with positive viral detection showed impaired lung function, with lower FEV1 and FVC values.</p></sec><sec id="ppul24214-sec-0004"><title>Conclusions</title><p>In our experience, viral respiratory tract infections can cause significant respiratory symptoms and impaired lung function, in children with HID, despite immunoglobulin replacement therapy. These patients could benefit from the monitoring of viral infections, as these may be a gateway for ongoing lung damage.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ppul24214-kwd-0001">humoral immunodeficiency</kwd><kwd id="ppul24214-kwd-0002">immunoglobulin replacement therapy</kwd><kwd id="ppul24214-kwd-0003">lung function</kwd><kwd id="ppul24214-kwd-0004">respiratory tract infection</kwd><kwd id="ppul24214-kwd-0005">virus</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>FIS (Fondo de Investigaciones Sanitarias &#x02212; Spanish Health Research Fund)</funding-source><award-id>PI15CIII/00028</award-id></award-group></funding-group><counts><fig-count count="0"/><table-count count="3"/><page-count count="6"/><word-count count="3576"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ppul24214-cit-000A">
<string-name>
<surname>Benavides&#x02010;Nieto</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>M&#x000e9;ndez&#x02010;Echevarr&#x000ed;a</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>del Rosal</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>The role of respiratory viruses in children with humoral immunodeficiency on immunoglobulin replacement therapy</article-title>. 
<source xml:lang="en">Pediatric Pulmonology</source>. 
<year>2019</year>;<volume>54</volume>:<fpage>194</fpage>&#x02013;<lpage>199</lpage>. <pub-id pub-id-type="doi">10.1002/ppul.24214</pub-id>
<pub-id pub-id-type="pmid">30575324</pub-id></mixed-citation>
</p><fn-group><fn id="ppul24214-note-0003"><p>Marta Benavides&#x02010;Nieto and Ana M&#x000e9;ndez&#x02010;Echevarr&#x000ed;a are share first authorship.</p></fn></fn-group></notes></front><body><sec id="ppul24214-sec-0005"><label>1</label><title>INTRODUCTION</title><p>Children with severe T&#x02010;cell immunodeficiencies present impaired clearance of respiratory viruses, and pulmonary complications of viral infections are leading causes of morbidity and mortality in this group of patients.<xref rid="ppul24214-bib-0001" ref-type="ref">1</xref>
</p><p>However, the role of respiratory viruses in children with other types of primary immunodeficiency (PID), mainly those with humoral immunodeficiencies (HID) or diseases of immune dysregulation, has hardly been studied.</p><p>Children with HID usually suffer from recurrent bacterial respiratory infections, resulting in progressive bronchiectasis and chronic lung disease.<xref rid="ppul24214-bib-0002" ref-type="ref">2</xref>, <xref rid="ppul24214-bib-0003" ref-type="ref">3</xref>, <xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>, <xref rid="ppul24214-bib-0005" ref-type="ref">5</xref> Immunoglobulin replacement therapy (IRT) reduces the frequency of these infections. However, despite adequate IRT, recurrent respiratory infections are still one of the leading causes of morbidity and mortality in these patients.<xref rid="ppul24214-bib-0002" ref-type="ref">2</xref>, <xref rid="ppul24214-bib-0003" ref-type="ref">3</xref>, <xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>
</p><p>Little data are currently available regarding the susceptibility to respiratory viruses of hypogammaglobulinemic patients receiving IRT.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>, <xref rid="ppul24214-bib-0006" ref-type="ref">6</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref> However, some other viruses have been described which play significant roles in these patients.<xref rid="ppul24214-bib-0008" ref-type="ref">8</xref>, <xref rid="ppul24214-bib-0009" ref-type="ref">9</xref>, <xref rid="ppul24214-bib-0010" ref-type="ref">10</xref>, <xref rid="ppul24214-bib-0011" ref-type="ref">11</xref> Human herpesvirus 8 (HHV&#x02010;8) has been associated with granulomatous/lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID),<xref rid="ppul24214-bib-0008" ref-type="ref">8</xref> and enterovirus is a known cause of fatal meningoencephalitis in patients with X&#x02010;linked agammaglobulinemia (XLA).<xref rid="ppul24214-bib-0009" ref-type="ref">9</xref>, <xref rid="ppul24214-bib-0010" ref-type="ref">10</xref> In addition, there are several recent reports showing an increased susceptibility to viral respiratory infections in adults with CVID receiving IRT,<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>, <xref rid="ppul24214-bib-0005" ref-type="ref">5</xref>, <xref rid="ppul24214-bib-0006" ref-type="ref">6</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref> that can contribute to chronic and persistent pulmonary inflammation.<xref rid="ppul24214-bib-0002" ref-type="ref">2</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref>
</p><p>We report, to the best of our knowledge, the first study that analyses respiratory viruses in pediatric patients with predominantly antibody deficiency who required IRT, considering their relationship with clinical symptoms and pulmonary function, bacterial co&#x02010;infection, treatment and outcomes.</p></sec><sec id="ppul24214-sec-0006"><label>2</label><title>PATIENTS AND METHODS</title><p>We conducted a prospective case&#x02010;control single&#x02010;center study during 1 year (November 2016 to October 2017) in a National Reference Unit for PID in Madrid, Spain.</p><p>We included patients less than 18 years of age diagnosed with HID who required IRT. Patients with combined immunodeficiency and/or reduced proliferative responses to mitogens (PHA, PWM, ConA) were excluded. Patients with HID who did not require IRT and/or patients receiving immunosuppressive treatments other than rituximab were excluded.</p><p>The study was approved by the local Clinical Research Ethics Committee. Informed consents were obtained from patients and parents.</p><p>For each patient, a healthy control was included, usually one of their parents. Respiratory samples (nasopharyngeal aspirate [NPA] for patients and nasopharyngeal swab for controls) were obtained every one to three months, coinciding with intravenous immunoglobulin administration or outpatient clinic evaluations, both in the patient and in the control group. Other investigations performed during the same visit in the patient group included: spirometry (in patients older than 5 years), spontaneous sputum culture (in patients older than 10 years), IgG levels, full blood count (FBC), C&#x02010;reactive protein, and erythrocyte sedimentation rate (ESR).</p><p>If patients developed respiratory symptoms between visits, additional sputum culture and nasopharyngeal aspirates were performed in the first 3 days after symptom onset, as well as an additional spirometry. In children older than 10 years of age who needed antibiotic for treating respiratory infections, the sputum samples were obtained before starting the therapy. Every moment in which a respiratory sample was obtained from a patient was defined as an episode.</p><p>Symptoms questionnaires elaborated ad hoc were filled out systematically biweekly by patients and controls, recording fever, increased respiratory secretions, cough, respiratory distress, sputum (increased production, change in its characteristics), absenteeism from school and/or work, need for steroids, bronchodilators or antibiotic therapy, and hospital admission. Respiratory symptoms for each subject in each episode were classified as none, mild or moderate/severe using a score based on the questionnaire (See supplementary file). Respiratory symptoms were classified as asymptomatic (0 points), mild symptoms (2 point or less), or moderate/severe symptoms (3 or more points).</p><p>Values are expressed as percentages for discrete variables, and as mean and standard deviation (SD) or median and interquartile range (IQR) for continuous variables. Due to the small number of patients included in both groups, no statistical comparisons were made.</p><sec id="ppul24214-sec-0007"><label>2.1</label><title>Respiratory tract infections and viruses: Microbiological analysis</title><p>NPA and nasopharyngeal swabs were sent for virological investigation to the Influenza and Respiratory Viruses Laboratory at the National Center for Microbiology (ISCIII), Madrid, Spain. Samples were processed within 24&#x02009;h after collection. Upon reception, three aliquots were prepared and stored at &#x02212;80&#x000b0;C. Both the reception and the NPA sample processing areas are separated from those defined as working areas.</p><p>Three independent RT&#x02010;PCR assays were performed to detect sixteen respiratory viruses as previously published by our group.<xref rid="ppul24214-bib-0012" ref-type="ref">12</xref>, <xref rid="ppul24214-bib-0013" ref-type="ref">13</xref>, <xref rid="ppul24214-bib-0014" ref-type="ref">14</xref> Influenza A, B, and C viruses were detected by using previously described primer sets only to amplify influenza viruses in a multiplex PCR assay.<xref rid="ppul24214-bib-0012" ref-type="ref">12</xref> A second multiplex PCR was used to detect parainfluenza viruses 1&#x02010;4, human coronaviruses 229E and OC43, enteroviruses, and rhinoviruses (RV).<xref rid="ppul24214-bib-0013" ref-type="ref">13</xref> Presence of respiratory syncityal virus (RSV) A and B types, human metapneumovirus, human bocavirus, and adenoviruses were investigated by a third multiplex RT&#x02010;nested PCR&#x02010;BRQ method.<xref rid="ppul24214-bib-0014" ref-type="ref">14</xref>
</p><p>Spontaneous sputum samples were collected using sterile specimen containers and immediately processed or stored at 4&#x000b0;C until processing was feasible. Samples were cultured on standard media, and potential respiratory tract pathogens were identified and tested for antimicrobial susceptibility.</p></sec><sec id="ppul24214-sec-0008"><label>2.2</label><title>Lung function testing</title><p>Pulmonary function tests were performed on all patients at study entry and repeated with every sample collection. Spirometry was performed according to established guidelines<xref rid="ppul24214-bib-0015" ref-type="ref">15</xref> using a Jaeger MasterScope&#x02010;PC spirometer (VIASYS HealthCare GmbH, Hoechberg, Germany). The <italic>Z</italic>&#x02010;scores were derived for each participant using norms from the Global Lung Function Initiative (GLI) basing specially on developed software (<italic>GLI&#x02010;2012 desktop software for individual calculations</italic>; <ext-link ext-link-type="uri" xlink:href="http://www.ers-education.org/guidelines/global-lung-function-initiative/spirometry-tools/desktop-individual-calculator.aspx">http://www.ers-education.org/guidelines/global-lung-function-initiative/spirometry-tools/desktop-individual-calculator.aspx</ext-link>). The GLI severity classification based on the FEV1 <italic>Z</italic> score was employed: mild (&#x02265;&#x02212;2.0), moderate (&#x02212;2.5 to &#x02212;2.0), moderately severe (&#x02212;3.0 to &#x02212;2.5), severe (&#x02212;4.0 to &#x02212;3.0), and very severe (&#x0003c;&#x02212;4.0)].<xref rid="ppul24214-bib-0016" ref-type="ref">16</xref>
</p></sec></sec><sec id="ppul24214-sec-0009"><label>3</label><title>RESULTS</title><p>During the study period, 14 patients with predominantly antibody deficiency were included (5 girls and 9 boys). Their main immunological diagnoses are reported in Table <xref rid="ppul24214-tbl-0001" ref-type="table">1</xref>.</p><table-wrap id="ppul24214-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients, diagnoses, pulmonary status at enrolment, and positive episodes</p></caption><table frame="below" rules="groups"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Case</th><th align="left" valign="bottom" rowspan="1" colspan="1">Diagnosis</th><th align="left" valign="bottom" rowspan="1" colspan="1">Bronchiectasis at enrolment</th><th align="left" valign="bottom" rowspan="1" colspan="1">Lung function at enrolment</th><th align="left" valign="bottom" rowspan="1" colspan="1">Gender</th><th align="left" valign="bottom" rowspan="1" colspan="1">Age: years</th><th align="left" valign="bottom" rowspan="1" colspan="1">Positive episodes</th><th align="left" valign="bottom" rowspan="1" colspan="1">Symptomatic during viral episodes</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">CTLA&#x02010;4 haploinsufficiency</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Restrictive</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1">ADV (January)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (April)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Coronavirus&#x02009;+&#x02009;RV (September)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">CVID</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Restrictive</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">RV (December)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (April)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (June)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Restrictive</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">16.9</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">XLA</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">18.8</td><td align="left" rowspan="1" colspan="1">RV (December)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Influenza A (February)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (September)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">17.8</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">ARA</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">7.8</td><td align="left" rowspan="1" colspan="1">RV (November)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (June)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">4.8</td><td align="left" rowspan="1" colspan="1">ADV (September)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (October)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ADV (November)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">B&#x02010;cell lymphopenia after HSCT due to CID more than 3 years ago</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">7.6</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">15.3</td><td align="left" rowspan="1" colspan="1">RSV(January)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">APDS2</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">14.9</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">AD&#x02010;HIES</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">RV (November)</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">RV (September)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">Secondary HID after rituximab for refractory nephrotic syndrome</td><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">NA</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">RV (December)</td><td align="left" rowspan="1" colspan="1">Yes</td></tr></tbody></table><table-wrap-foot><fn id="ppul24214-note-0001"><p>AD&#x02010;HIES, autosomal dominant Hyper IgE syndrome; ADV, adenovirus; APDS2, activated PI3 kinase delta syndrome; ARA, autosomal recessive agammaglobulinemia; CID, combined immunodeficiency; CVID, common variable immunodeficiency; HID, humoral immunodeficiency; HSCT, hematopoietic stem cell transplantation; NA, not available (young children); RSV, respiratory syncytial virus; RV, rhinovirus; XLA, X&#x02010;linked agammaglobulinemia.</p></fn></table-wrap-foot><permissions><copyright-holder>&#x000a9; 2018 Wiley Periodicals, Inc.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>The median age of patients was 12 years (IQR 7&#x02010;17), and only two of them were younger than 5 years. Eleven patients were receiving intravenous IRT and three patients, subcutaneous IRT. Immunological status at inclusion is described in Table <xref rid="ppul24214-tbl-0002" ref-type="table">2</xref>.</p><table-wrap id="ppul24214-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Immunologic studies of cases at the moment of inclusion (<italic>n</italic>&#x02009;=&#x02009;14)</p></caption><table frame="below" rules="groups"><col span="1"/><col span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Median values</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Median neutrophil count</td><td align="left" rowspan="1" colspan="1">3400/&#x003bc;L (IQR; 1355&#x02010;4970)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median lymphocyte count</td><td align="left" rowspan="1" colspan="1">1470/&#x003bc;L (IQR; 1092&#x02010;2185)</td></tr><tr><td colspan="2" align="left" rowspan="1">Median T&#x02010;cells</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CD3+ % (count)</td><td align="left" rowspan="1" colspan="1">89.5% (1347/&#x003bc;L; IQR 830&#x02010;1977)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CD4+ % (count)</td><td align="left" rowspan="1" colspan="1">44.5% (555/&#x003bc;L; IQR 400&#x02010;975)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CD8&#x02009;+&#x02009;% (count)</td><td align="left" rowspan="1" colspan="1">38% (706/&#x003bc;L; IQR 257&#x02010;825)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median B&#x02010;cells CD19+ % (count)</td><td align="left" rowspan="1" colspan="1">4% (53/&#x003bc;L; IQR 0&#x02010;164)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median NK&#x02010;cells CD56&#x02009;+&#x02009;CD3&#x02212; % (count)</td><td align="left" rowspan="1" colspan="1">7% (89/&#x003bc;L; IQR 47&#x02010;210)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median IgA</td><td align="left" rowspan="1" colspan="1">0&#x02009;mg/dL (IQR; 0&#x02010;16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Median IgM</td><td align="left" rowspan="1" colspan="1">42&#x02009;mg/dL (IQR; 1&#x02010;150)</td></tr></tbody></table><permissions><copyright-holder>&#x000a9; 2018 Wiley Periodicals, Inc.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap><p>Eighteen healthy adult family members (mother and/or father) of the patients were included as healthy control subjects (at least one control per case included).</p><p>Sixty&#x02010;six episodes were analyzed in 14 patients (median number of samples per patient: 4; IQR 1&#x02010;6). There were 18 (27.3%) with a positive viral detection: 12 rhinovirus, 3 adenovirus, and 1 case each of influenza&#x02010;A, respiratory syncytial virus (RSV), and coinfection rhinovirus&#x02010;coronavirus (Table <xref rid="ppul24214-tbl-0001" ref-type="table">1</xref>). Six patients had no positive samples, coinciding with those who had fewer number of samples collected. The median of positive samples per patient was 1 (IQR 0&#x02010;3).</p><p>A total of 57 respiratory samples were collected from healthy controls, and viruses were identified in 12 (21%): eight rhinovirus, three coronavirus, and one influenza. Only in two occasions (2/18; 11%) the same virus (rhinovirus) was simultaneously identified in both patient and control episodes. No significant differences were found regarding the viral isolation rate between patients and healthy controls.</p><p>Sputum cultures were available in 19 episodes of older children, being positive in 16 (84%). <italic>Haemophilus influenzae</italic> was isolated in all cases but one (co&#x02010;isolation of <italic>Streptococcus pneumoniae</italic>/<italic>Pseudomonas aeruginosa</italic>).</p><p>IgG levels were available in 47 episodes. In six of them (15%) they were &#x0003c;600&#x02009;mg/dL.</p><p>Median IgA level was 0 (IQR 0&#x02010;14.7).</p><sec id="ppul24214-sec-0010"><label>3.1</label><title>Comparison between episodes with positive and negative viral detection</title><p>Episodes with positive viral detection (<italic>n</italic>&#x02009;=&#x02009;18) were associated with respiratory symptoms in 89% of cases (16/18) and 44% of controls.</p><p>Regarding respiratory symptoms in the viral positive cases, 27.8% (5/18) of them were mild, 61.1% moderate/severe (11/18) and, only 2 (11%) were asymptomatic. Episodes with negative viral detection were less frequently associated with respiratory symptoms than positive episodes 42.5% (20/47) versus 89% (16/18) with 25.5% of them presenting mild symptoms and 38.3% severe. Episodes with positive viral detection were associated with impaired lung function, higher levels of antibiotic prescribing and hospital admission (Table <xref rid="ppul24214-tbl-0003" ref-type="table">3</xref>).</p><table-wrap id="ppul24214-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Comparison between episodes with positive and negative viral detection in children with humoral immunodeficiencies</p></caption><table frame="below" rules="groups"><col span="1"/><col span="1"/><col span="1"/><thead valign="bottom"><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Negative&#x02010;virus episodes</th><th align="left" valign="bottom" rowspan="1" colspan="1">Positive&#x02010;virus episodes</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Number of episodes</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">No symptoms</td><td align="left" rowspan="1" colspan="1">57% (27/47)</td><td align="left" rowspan="1" colspan="1">11% (2/18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Bronchodilator treatment</td><td align="left" rowspan="1" colspan="1">15% (7/47)</td><td align="left" rowspan="1" colspan="1">2% (4/18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotic treatment</td><td align="left" rowspan="1" colspan="1">15% (7/47)</td><td align="left" rowspan="1" colspan="1">44% (8/18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital admission</td><td align="left" rowspan="1" colspan="1">0% (0/48)</td><td align="left" rowspan="1" colspan="1">22% (4/18)</td></tr><tr><td align="left" rowspan="1" colspan="1">IgG levels&#x02009;&#x0003c;600&#x02009;mg/dL</td><td align="left" rowspan="1" colspan="1">15% (5/34)</td><td align="left" rowspan="1" colspan="1">15% (2/13)</td></tr><tr><td align="left" rowspan="1" colspan="1">IgA levels mg/dL (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">7&#x02009;&#x000b1;&#x02009;11</td><td align="left" rowspan="1" colspan="1">11&#x02009;&#x000b1;&#x02009;13</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood lymphocyte count (cells/mm<sup>3</sup>) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">1485&#x02009;&#x000b1;&#x02009;598</td><td align="left" rowspan="1" colspan="1">1505&#x02009;&#x000b1;&#x02009;632</td></tr><tr><td align="left" rowspan="1" colspan="1">C reactive protein (mg/L) (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">3.9&#x02009;&#x000b1;&#x02009;3</td><td align="left" rowspan="1" colspan="1">2.6&#x02009;&#x000b1;&#x02009;3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>H influenzae</italic> in sputum culture</td><td align="left" rowspan="1" colspan="1">93% (13/14)</td><td align="left" rowspan="1" colspan="1">40% (2/5)</td></tr><tr><td align="left" rowspan="1" colspan="1">FEV1&#x02009;&#x0003c;&#x02009;80% and/or FEV1/FVC&#x02009;&#x0003c;&#x02009;70</td><td align="left" rowspan="1" colspan="1">24% (9/37)</td><td align="left" rowspan="1" colspan="1">70% (7/10)</td></tr><tr><td align="left" rowspan="1" colspan="1">FVC&#x02009;&#x0003c;&#x02009;80%</td><td align="left" rowspan="1" colspan="1">16% (6/37)</td><td align="left" rowspan="1" colspan="1">70% (7/10)</td></tr><tr><td align="left" rowspan="1" colspan="1">%FEV1 (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">96&#x02009;&#x000b1;&#x02009;16</td><td align="left" rowspan="1" colspan="1">84&#x02009;&#x000b1;&#x02009;11</td></tr><tr><td align="left" rowspan="1" colspan="1">%FVC (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">96.3&#x02009;&#x000b1;&#x02009;18</td><td align="left" rowspan="1" colspan="1">82.5&#x02009;&#x000b1;&#x02009;14</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>z</italic> score FEV1 (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9&#x02009;&#x000b1;&#x02009;1.1</td><td align="left" rowspan="1" colspan="1">&#x02212;1.8&#x02009;&#x000b1;&#x02009;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>z</italic> score FVC (mean&#x02009;&#x000b1;&#x02009;SD)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.7&#x02009;&#x000b1;&#x02009;1.3</td><td align="left" rowspan="1" colspan="1">&#x02212;1.8&#x02009;&#x000b1;&#x02009;1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>z</italic> score FEV1&#x02009;&#x0003c;&#x02009;&#x02212;2</td><td align="left" rowspan="1" colspan="1">19% (7/37)</td><td align="left" rowspan="1" colspan="1">50% (5/10)</td></tr></tbody></table><table-wrap-foot><fn id="ppul24214-note-0002"><p>FEV1, forced expiratory volume in first second; FVC, forced vital capacity; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>&#x000a9; 2018 Wiley Periodicals, Inc.</copyright-holder><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions></table-wrap></sec></sec><sec id="ppul24214-sec-0011"><label>4</label><title>DISCUSSION</title><p>Our results suggest that viral respiratory tract infections may play an important role in children with predominantly antibody deficiencies. In our experience, presence of respiratory symptoms, negative bacterial sputum culture, impaired lung function, antibiotic prescription, and hospital admission were significantly associated with viral detection.</p><p>Some authors have already reported how respiratory viral infections seem to play a role in adults with HID.<xref rid="ppul24214-bib-0007" ref-type="ref">7</xref>, <xref rid="ppul24214-bib-0008" ref-type="ref">8</xref>, <xref rid="ppul24214-bib-0009" ref-type="ref">9</xref>, <xref rid="ppul24214-bib-0010" ref-type="ref">10</xref>, <xref rid="ppul24214-bib-0011" ref-type="ref">11</xref>, <xref rid="ppul24214-bib-0012" ref-type="ref">12</xref>, <xref rid="ppul24214-bib-0013" ref-type="ref">13</xref>, <xref rid="ppul24214-bib-0014" ref-type="ref">14</xref>, <xref rid="ppul24214-bib-0015" ref-type="ref">15</xref>, <xref rid="ppul24214-bib-0016" ref-type="ref">16</xref>, <xref rid="ppul24214-bib-0017" ref-type="ref">17</xref> These studies have reported viral detection rates in 41&#x02010;56% of respiratory exacerbations, being rhinovirus the most frequently identified.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>, <xref rid="ppul24214-bib-0005" ref-type="ref">5</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref> These episodes are more frequently symptomatic in HID patients compared to healthy controls,<xref rid="ppul24214-bib-0006" ref-type="ref">6</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref> as we have observed.</p><p>However, the role of viral respiratory infections in children with HID has hardly been analyzed, and the mechanisms of increased susceptibility to some viral respiratory infections in these patients are not well known.<xref rid="ppul24214-bib-0017" ref-type="ref">17</xref>
</p><p>IRT may not offer protection at the mucosal surface, as IgA and IgM are not replaced with immunoglobulin products.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref> IgM is highly effective for agglutination, especially of viruses.<xref rid="ppul24214-bib-0017" ref-type="ref">17</xref> In addition, Duraisingham et al observed that patients with HID and respiratory viral infection presented lower levels of IgA than patients with negative viral results.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref> In our series, patients with positive viral detection presented adequate IgG levels, but very low IgA levels, which could favor these infections.</p><p>Some authors have also suggested that antibodies originating in the lymphatic tissue of the respiratory mucosa may play a more important role than systemic antibodies against pulmonary and sinus infection.<xref rid="ppul24214-bib-0003" ref-type="ref">3</xref>, <xref rid="ppul24214-bib-0017" ref-type="ref">17</xref> In addition, persistent viral infections could result in chronic antigen stimulation in the context of a dysregulated immune system, and could exacerbate inflammatory disorders.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref>, <xref rid="ppul24214-bib-0007" ref-type="ref">7</xref>
</p><p>In our study, bacterial sputum cultures were more frequently positive in children with negative virological tests. However, antibiotic prescription was higher in patients with viral respiratory infection, as an important percentage of our patients with positive viral episodes associated respiratory symptoms, and the results of viral tests were not available early during the episode. Duraisingham et al observed that most positive viral samples of their study were obtained from patients with negative bacteriologic results.<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref> Sperlich et al also reported that viruses are commonly present in adults with CVID and upper respiratory tract symptoms that respond poorly to antibiotics,<xref rid="ppul24214-bib-0005" ref-type="ref">5</xref> suggesting that antibiotic usage could be better targeted.</p><p>On the other hand, other authors have hypothesized that persistent and recurrent viral respiratory infections could adversely affect the microbiome, leading to an increased bacterial density in children's nasopharyngeal tract, predisposing to sinopulmonary bacterial infections.<xref rid="ppul24214-bib-0017" ref-type="ref">17</xref>, <xref rid="ppul24214-bib-0018" ref-type="ref">18</xref> As other authors,<xref rid="ppul24214-bib-0004" ref-type="ref">4</xref> we recommend screening for viral infection in children with HID and acute respiratory symptoms to avoid unnecessary antibiotic treatment. However, viral testing is routinely performed only in children with severe combined immunodeficiency (SCID).<xref rid="ppul24214-bib-0001" ref-type="ref">1</xref>, <xref rid="ppul24214-bib-0004" ref-type="ref">4</xref> Regarding HID, protocols present a great deal of variation across Europe in the management of lung complications.<xref rid="ppul24214-bib-0019" ref-type="ref">19</xref> There is an urgent need for consensus guidelines on how to monitor lung complications and how to treat respiratory infections in HID patients.<xref rid="ppul24214-bib-0019" ref-type="ref">19</xref>
</p><p>Not all our patients were typical HID such as XLA or CVID. Three of our cases were SCID patients who had received a hematopoietic cell transplant, but presented persistent B&#x02010;cell lymphopenia and hypogammaglobulinemia. Although most children with SCID recover cellular immunity 1 year after transplantation, many patients are likely to be on IRT for a considerable period until full reconstitution of B&#x02010;cell immunity has been achieved.<xref rid="ppul24214-bib-0020" ref-type="ref">20</xref>, <xref rid="ppul24214-bib-0021" ref-type="ref">21</xref> B&#x02010;cell immune reconstitution and its consequences regarding viral respiratory infections have not been deeply investigated in these patients. Our data support that these patients are also prone to viral respiratory infections, which impact lung function and lead to antibiotic consumption.</p><p>Another patient was an AD&#x02010;HIES. Regarding humoral immunity, many patients with AD&#x02010;HIES require immunoglobulin infusions due to memory B&#x02010;cell lymphopenia and decline in specific antibody titers.<xref rid="ppul24214-bib-0022" ref-type="ref">22</xref> Recurrent respiratory tract infections have been described in these children, and more than 90% of them develop pneumonia.<xref rid="ppul24214-bib-0022" ref-type="ref">22</xref> Although bacteria are detected in 44% of respiratory exacerbations, viral pneumonia has also been reported.<xref rid="ppul24214-bib-0022" ref-type="ref">22</xref> Lung sequelae in these patients are frequent, mainly as bronchiectasis.<xref rid="ppul24214-bib-0022" ref-type="ref">22</xref> Thus, monitoring viral infections in these children may be important.</p><p>One patient in our series suffered from APDS2. While the disease is heterogeneous, respiratory infections and their complications are frequent and often severe.<xref rid="ppul24214-bib-0023" ref-type="ref">23</xref> The spectrum of pathogens is highly reminiscent of other primary antibody deficiency syndromes such as CVID.<xref rid="ppul24214-bib-0023" ref-type="ref">23</xref> Coulter et al<xref rid="ppul24214-bib-0024" ref-type="ref">24</xref> noted that significant adenovirus infections occurred in 17% of their cohort; other viruses commonly identified during respiratory exacerbations included RSV, parainfluenza, echovirus, and coxsackie.</p><p>Finally, one patient had no PID, but he developed persistent B&#x02010;cell lymphopenia with secondary hypogammaglobulinemia requiring IRT 1 year after receiving rituximab for treating steroid&#x02010;resistant nephrotic syndrome. Rituximab was the first anti&#x02010;CD20 monoclonal antibody, and the development of persistent hypogammaglobinemia after its use has been reported in children.<xref rid="ppul24214-bib-0025" ref-type="ref">25</xref> Recent clinical studies highlight that some patients may develop a clinical condition similar to CVID, with the degree of hypogammaglobulinemia being directly associated with infection rates.<xref rid="ppul24214-bib-0023" ref-type="ref">23</xref> These infections, including severe respiratory tract infection, remain the most common non&#x02010;hematological adverse effect of anti&#x02010;CD20 monoclonal antibodies.<xref rid="ppul24214-bib-0025" ref-type="ref">25</xref> However, the clinical impact of hypogammaglobulinemia induced by CD20&#x02010;targeted therapy remains unclear.</p><p>Our study has several limitations. We have included a small number of patients who suffer from different types of HID with varying molecular mechanisms. Despite the heterogeneity of the cases, our results indicate the significant role of viral respiratory infections in these children, in terms of clinical symptoms, lung function, antibiotic prescription, and hospital admission. We have also observed that viral isolation is more frequently associated with symptoms in cases compared with healthy controls although both groups are different in terms of age and immunity and do not allow direct comparisons. Further studies should ideally include age&#x02010;matched healthy controls, to better assess the impact of viral infections in children with humoral immunodeficiency. However, Peltola et al<xref rid="ppul24214-bib-0006" ref-type="ref">6</xref> have reported that the duration of symptoms and of rhinovirus shedding was longer in adults with HID than in healthy children. For this reason, we expect that respiratory viruses might cause more symptoms in these patients compared with healthy children, although we have not been able to prove it. In spite of the limitations, respiratory viral infections seem to play a role in children with HID, as has also been described in adults.<xref rid="ppul24214-bib-0007" ref-type="ref">7</xref>, <xref rid="ppul24214-bib-0017" ref-type="ref">17</xref>
</p><p>Further studies are needed to improve our knowledge about the impact of respiratory viral infections, their prevention and management in children with IRT, with the aim of avoiding short&#x02010; and long&#x02010;term consequences.</p></sec><sec sec-type="COI-statement" id="ppul24214-sec-0013"><title>CONFLICT OF INTEREST</title><p>The authors declare no conflict of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><p>Additional supporting information may be found online in the Supporting Information section at the end of the article.</p></supplementary-material><supplementary-material content-type="local-data"><caption><p>Supporting Information S1.</p></caption><media xlink:href="PPUL-54-194-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="ppul24214-sec-0012"><title>ACKNOWLEDGMENTS</title><p>To Claire Marsden for the revision of the English language. This study has been partially supported by FIS (Fondo de Investigaciones Sanitarias&#x02014;Spanish Health Research Fund) Grant No. PI15CIII/00028.</p></ack><ref-list id="ppul24214-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="ppul24214-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ppul24214-cit-0001">
<string-name>
<surname>M&#x000e9;ndez&#x02010;Echevarr&#x000ed;a</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Del Rosal</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>P&#x000e9;rez&#x02010;Costa</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Clinical features before hematopoietic stem cell transplantation or enzyme replacement therapy of children with combined immunodeficiency</article-title>. 
<source xml:lang="en">Pediatr Infect Dis J</source>. 
<year>2016</year>;<volume>35</volume>:<fpage>794</fpage>&#x02013;<lpage>798</lpage>.
<pub-id pub-id-type="pmid">27078120</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ppul24214-cit-0002">
<string-name>
<surname>Verma</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Grimbacher</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Hurst</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Lung disease in primary antibody deficiency</article-title>. 
<source xml:lang="en">Lancet Respir Med</source>. 
<year>2015</year>;<volume>3</volume>:<fpage>651</fpage>&#x02013;<lpage>660</lpage>.
<pub-id pub-id-type="pmid">26188881</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ppul24214-cit-0003">
<string-name>
<surname>Jolles</surname>
<given-names>S</given-names>
</string-name>. <article-title>Subclinical infection and dosing in primary immunodeficiencies</article-title>. 
<source xml:lang="en">Clin Exp Immunol</source>. 
<year>2014</year>;<volume>178</volume>:<fpage>67</fpage>&#x02013;<lpage>69</lpage>.
<pub-id pub-id-type="pmid">25546767</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ppul24214-cit-0004">
<string-name>
<surname>Duraisingham</surname>
<given-names>SS</given-names>
</string-name>, 
<string-name>
<surname>Manson</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Grigoriadou</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Buckland</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Tong</surname>
<given-names>CY</given-names>
</string-name>, 
<string-name>
<surname>Longhurst</surname>
<given-names>HJ</given-names>
</string-name>. <article-title>Immune deficiency: changing spectrum of pathogens</article-title>. 
<source xml:lang="en">Clin Exp Immunol</source>. 
<year>2015</year>;<volume>181</volume>:<fpage>267</fpage>&#x02013;<lpage>274</lpage>.
<pub-id pub-id-type="pmid">25677249</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ppul24214-cit-0005">
<string-name>
<surname>Sperlich</surname>
<given-names>JM</given-names>
</string-name>, 
<string-name>
<surname>Grimbacher</surname>
<given-names>B</given-names>
</string-name>, 
<string-name>
<surname>Workman</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Respiratory infections and antibiotic usage in common variable immunodeficiency</article-title>. 
<source xml:lang="en">J Allergy Clin Immunol Pract</source>. 
<year>2018</year>;<volume>6</volume>:<fpage>159</fpage>&#x02013;<lpage>168.e3</lpage>.
<pub-id pub-id-type="pmid">28734862</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ppul24214-cit-0006">
<string-name>
<surname>Peltola</surname>
<given-names>V</given-names>
</string-name>, 
<string-name>
<surname>Waris</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Kainulainen</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Kero</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Ruuskanen</surname>
<given-names>O</given-names>
</string-name>. <article-title>Virus shedding after human rhinovirus infection in children, adults and patients with hypogammaglobulinaemia</article-title>. 
<source xml:lang="en">Clin Microbiol Infect</source>. 
<year>2013</year>;<volume>19</volume>:<fpage>E322</fpage>&#x02013;<lpage>E327</lpage>.
<pub-id pub-id-type="pmid">23490188</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ppul24214-cit-0007">
<string-name>
<surname>Kainulainen</surname>
<given-names>L</given-names>
</string-name>, 
<string-name>
<surname>Vuorinen</surname>
<given-names>T</given-names>
</string-name>, 
<string-name>
<surname>Rantakokko&#x02010;Jalava</surname>
<given-names>K</given-names>
</string-name>, 
<string-name>
<surname>&#x000d6;sterback</surname>
<given-names>R</given-names>
</string-name>, 
<string-name>
<surname>Ruuskanen</surname>
<given-names>O</given-names>
</string-name>. <article-title>Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia</article-title>. 
<source xml:lang="en">J Allergy Clin Immunol</source>. 
<year>2010</year>;<volume>126</volume>:<fpage>120</fpage>&#x02013;<lpage>126</lpage>.
<pub-id pub-id-type="pmid">20541246</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ppul24214-cit-0008">
<string-name>
<surname>Park</surname>
<given-names>JH</given-names>
</string-name>, 
<string-name>
<surname>Levinson</surname>
<given-names>AI</given-names>
</string-name>. <article-title>Granulomatous&#x02010;lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)</article-title>. 
<source xml:lang="en">Clin Immunol</source>. 
<year>2010</year>;<volume>134</volume>:<fpage>97</fpage>&#x02013;<lpage>103</lpage>.
<pub-id pub-id-type="pmid">19900842</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ppul24214-cit-0009">
<string-name>
<surname>Bearden</surname>
<given-names>D</given-names>
</string-name>, 
<string-name>
<surname>Collett</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Quan</surname>
<given-names>PL</given-names>
</string-name>, 
<string-name>
<surname>Costa&#x02010;Carvalho</surname>
<given-names>BT</given-names>
</string-name>, 
<string-name>
<surname>Sullivan</surname>
<given-names>KE</given-names>
</string-name>. <article-title>Enteroviruses in X&#x02010;linked agammaglobulinemia: update on epidemiology and therapy</article-title>. 
<source xml:lang="en">J Allergy Clin Immunol Pract</source>. 
<year>2016</year>;<volume>4</volume>:<fpage>1059</fpage>&#x02013;<lpage>1065</lpage>.
<pub-id pub-id-type="pmid">26883540</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ppul24214-cit-0010">
<string-name>
<surname>Winkelstein</surname>
<given-names>JA</given-names>
</string-name>, 
<string-name>
<surname>Marino</surname>
<given-names>MC</given-names>
</string-name>, 
<string-name>
<surname>Lederman</surname>
<given-names>HM</given-names>
</string-name>, et al. <article-title>X&#x02010;linked agammaglobulinemia: report on a United States registry of 201 patients</article-title>. 
<source xml:lang="en">Medicine (Baltimore)</source>. 
<year>2006</year>;<volume>85</volume>:<fpage>193</fpage>&#x02013;<lpage>202</lpage>.
<pub-id pub-id-type="pmid">16862044</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ppul24214-cit-0011">
<string-name>
<surname>Rezaei</surname>
<given-names>N</given-names>
</string-name>, 
<string-name>
<surname>Hedayat</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Aghamohammadi</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Nichols</surname>
<given-names>KE</given-names>
</string-name>. <article-title>Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies</article-title>. 
<source xml:lang="en">J Allergy Clin Immunol</source>. 
<year>2011</year>;<volume>127</volume>:<fpage>1329</fpage>&#x02013;<lpage>41.e2</lpage>.
<pub-id pub-id-type="pmid">21514636</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ppul24214-cit-0012">
<string-name>
<surname>Coiras</surname>
<given-names>MT</given-names>
</string-name>, 
<string-name>
<surname>Perez&#x02010;Brena</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Garcia</surname>
<given-names>ML</given-names>
</string-name>, 
<string-name>
<surname>Casas</surname>
<given-names>I</given-names>
</string-name>. <article-title>Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in clinical samples by multiplex reverse transcription nested&#x02010;PCR assay</article-title>. 
<source xml:lang="en">J Med Virol</source>. 
<year>2003</year>;<volume>69</volume>:<fpage>132</fpage>&#x02013;<lpage>144</lpage>.
<pub-id pub-id-type="pmid">12436489</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ppul24214-cit-0013">
<string-name>
<surname>Coiras</surname>
<given-names>MT</given-names>
</string-name>, 
<string-name>
<surname>Aguilar</surname>
<given-names>JC</given-names>
</string-name>, 
<string-name>
<surname>Garcia</surname>
<given-names>ML</given-names>
</string-name>, 
<string-name>
<surname>Casas</surname>
<given-names>I</given-names>
</string-name>, 
<string-name>
<surname>P&#x000e9;rez&#x02010;Bre&#x000f1;a</surname>
<given-names>P</given-names>
</string-name>. <article-title>Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested&#x02010;PCR assays</article-title>. 
<source xml:lang="en">J Med Virol</source>. 
<year>2004</year>;<volume>72</volume>:<fpage>484</fpage>&#x02013;<lpage>495</lpage>.
<pub-id pub-id-type="pmid">14748074</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ppul24214-cit-0014">
<string-name>
<surname>Calvo</surname>
<given-names>C</given-names>
</string-name>, 
<string-name>
<surname>Pozo</surname>
<given-names>F</given-names>
</string-name>, 
<string-name>
<surname>Garc&#x000ed;a&#x02010;Garc&#x000ed;a</surname>
<given-names>ML</given-names>
</string-name>, et al. <article-title>Detection of new respiratory viruses in hospitalized infants with bronchiolitis: a three&#x02010;year prospective study</article-title>. 
<source xml:lang="en">Acta Pediatr</source>. 
<year>2010</year>;<volume>99</volume>:<fpage>883</fpage>&#x02013;<lpage>887</lpage>.
</mixed-citation></ref><ref id="ppul24214-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ppul24214-cit-0015">
<string-name>
<surname>Miller</surname>
<given-names>MR</given-names>
</string-name>, 
<string-name>
<surname>Hankinson</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Brusasco</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Standardisation of spirometry</article-title>. 
<source xml:lang="en">Eur Respir J</source>. 
<year>2005</year>;<volume>26</volume>:<fpage>319</fpage>&#x02013;<lpage>338</lpage>.
<pub-id pub-id-type="pmid">16055882</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ppul24214-cit-0016">
<string-name>
<surname>Quanjer</surname>
<given-names>PH</given-names>
</string-name>, 
<string-name>
<surname>Pretto</surname>
<given-names>JJ</given-names>
</string-name>, 
<string-name>
<surname>Brazzale</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Grading the severity of airways obstruction: new wine in new bottles</article-title>. 
<source xml:lang="en">Eur Respir J</source>. 
<year>2014</year>;<volume>43</volume>:<fpage>505</fpage>&#x02013;<lpage>512</lpage>.
<pub-id pub-id-type="pmid">23988764</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ppul24214-cit-0017">
<string-name>
<surname>Baumann</surname>
<given-names>U</given-names>
</string-name>, 
<string-name>
<surname>Routes</surname>
<given-names>JM</given-names>
</string-name>, 
<string-name>
<surname>Soler&#x02010;Palac&#x000ed;n</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Jolles</surname>
<given-names>S</given-names>
</string-name>. <article-title>The lung in primary immunodeficiencies: new concepts in infection and inflammation</article-title>. 
<source xml:lang="en">Front Immunol</source>. 
<year>2018</year>;<volume>9</volume>:<fpage>1837</fpage>.
<pub-id pub-id-type="pmid">30147696</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ppul24214-cit-0018">
<string-name>
<surname>Molyneaux</surname>
<given-names>PL</given-names>
</string-name>, 
<string-name>
<surname>Mallia</surname>
<given-names>P</given-names>
</string-name>, 
<string-name>
<surname>Cox</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease</article-title>. 
<source xml:lang="en">Am J Respir Crit Care Med</source>. 
<year>2013</year>;<volume>188</volume>:<fpage>1224</fpage>&#x02013;<lpage>1231</lpage>.
<pub-id pub-id-type="pmid">23992479</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ppul24214-cit-0019">
<string-name>
<surname>Jolles</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>S&#x000e1;nchez&#x02010;Ram&#x000f3;n</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Quinti</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group</article-title>. 
<source xml:lang="en">Clin Exp Immunol</source>. 
<year>2017</year>;<volume>190</volume>:<fpage>226</fpage>&#x02013;<lpage>234</lpage>.
<pub-id pub-id-type="pmid">28708268</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ppul24214-cit-0020">
<string-name>
<surname>Heimall</surname>
<given-names>J</given-names>
</string-name>, 
<string-name>
<surname>Logan</surname>
<given-names>BR</given-names>
</string-name>, 
<string-name>
<surname>Cowan</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Immune reconstitution and survival of 100 SCID patients post&#x02010;hematopoietic cell transplant: a PIDTC natural history study</article-title>. 
<source xml:lang="en">Blood</source>. 
<year>2017</year>;<volume>130</volume>:<fpage>2718</fpage>&#x02013;<lpage>2727</lpage>.
<pub-id pub-id-type="pmid">29021228</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ppul24214-cit-0021">
<string-name>
<surname>Lev</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Simon</surname>
<given-names>AJ</given-names>
</string-name>, 
<string-name>
<surname>Bareket</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The kinetics of early T and B cell immune recovery after bone marrow transplantation in RAG&#x02010;2&#x02010;deficient SCID patients</article-title>. 
<source xml:lang="en">PLoS ONE</source>. 
<year>2012</year>;<volume>7</volume>:<fpage>e30494</fpage>.
<pub-id pub-id-type="pmid">22295088</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ppul24214-cit-0022">
<string-name>
<surname>Chandesris</surname>
<given-names>MO</given-names>
</string-name>, 
<string-name>
<surname>Melki</surname>
<given-names>I</given-names>
</string-name>, 
<string-name>
<surname>Natividad</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Autosomal dominant STAT3 deficiency and hyper&#x02010;IgE syndrome: molecular, cellular, and clinical features from a French national survey</article-title>. 
<source xml:lang="en">Medicine (Baltimore)</source>. 
<year>2012</year>;<volume>91</volume>:<fpage>e1</fpage>&#x02013;<lpage>19</lpage>.
<pub-id pub-id-type="pmid">22751495</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ppul24214-cit-0023">
<string-name>
<surname>Condliffe</surname>
<given-names>AM</given-names>
</string-name>, 
<string-name>
<surname>Chandra</surname>
<given-names>A</given-names>
</string-name>. <article-title>Respiratory manifestations of the activated phosphoinositide 3&#x02010;kinase delta syndrome</article-title>. 
<source xml:lang="en">Front Immunol</source>. 
<year>2018</year>;<volume>9</volume>:<fpage>338</fpage>.
<pub-id pub-id-type="pmid">29556229</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ppul24214-cit-0024">
<string-name>
<surname>Coulter</surname>
<given-names>TI</given-names>
</string-name>, 
<string-name>
<surname>Chandra</surname>
<given-names>A</given-names>
</string-name>, 
<string-name>
<surname>Bacon</surname>
<given-names>CM</given-names>
</string-name>, et al. <article-title>Clinical spectrum and features of activated phosphoinositide 3&#x02010;kinase &#x003b4; syndrome: a large patient cohort study</article-title>. 
<source xml:lang="en">J Allergy Clin Immunol</source>. 
<year>2017</year>;<volume>139</volume>:<fpage>597.e</fpage>&#x02013;<lpage>606.e</lpage>.
<pub-id pub-id-type="pmid">27555459</pub-id></mixed-citation></ref><ref id="ppul24214-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ppul24214-cit-0025">
<string-name>
<surname>Mikulska</surname>
<given-names>M</given-names>
</string-name>, 
<string-name>
<surname>Lanini</surname>
<given-names>S</given-names>
</string-name>, 
<string-name>
<surname>Gudiol</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)</article-title>. 
<source xml:lang="en">Clin Microbiol Infect</source>. 
<year>2018</year>;<volume>24</volume>:<fpage>S71</fpage>&#x02013;<lpage>S82</lpage>.
<pub-id pub-id-type="pmid">29447988</pub-id></mixed-citation></ref></ref-list></back></article>